Idvynso-Doravirine And Islatravir
Idvynso is a prescription oral therapy indicated as a complete regimen for the treatment of HIV-1 infection in adults who are already virologically suppressed on a stable antiretroviral regimen. Designed to replace an existing treatment in patients with no history of virologic failure and no known resistance to Doravirine, a next-generation non-nucleoside reverse transcriptase inhibitor […]
Foundayo-Orforglipron
Foundayo is an oral, once-daily, investigational GLP-1 receptor pathway targeting therapy for chronic weight management in adults with obesity. Unlike injectable GLP-1 receptor agonists, orforglipron is a small-molecule, non-peptide option designed for convenient administration without food or water restrictions. Its mechanism focuses on appetite regulation, increased satiety, and reduced caloric intake, addressing key biological drivers […]
Icotyde-Icotrokinra Hydrochloride
Icotyde is a prescription medication indicated for the treatment of moderate-to-severe plaque psoriasis in patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Unlike topical treatments, Icotyde is intended for patients requiring systemic intervention, helping manage widespread or treatment-resistant disease. It works by […]
Lynavoy-Linerixibat
Lynavoy (linerixibat) is a prescription medication used in adults to treat cholestatic pruritus associated with primary biliary cholangitis (PBC), a chronic liver disease marked by bile acid buildup and persistent itching. Unlike conventional symptomatic treatments, Lynavoy works by inhibiting the ileal bile acid transporter (IBAT) in the intestine, reducing bile acid reabsorption and promoting their […]
Lifyorli-Relacorilant
Lifyorli (relacorilant) is a prescription medication used in combination with chemotherapy to treat advanced ovarian, fallopian tube, or primary peritoneal cancer in adults who have undergone prior treatments. Unlike conventional therapies, Lifyorli works as a selective glucocorticoid receptor antagonist, helping reduce tumor resistance and enhancing the effectiveness of chemotherapy. Advanced cancers often present challenges such […]
Myrbetriq-Mirabegron
Myrbetriq (mirabegron) is a prescription medication used in adults to manage overactive bladder (OAB), a condition characterized by urgency, increased frequency of urination, and urge-related leakage. Unlike traditional antimuscarinic therapies, Myrbetriq works through a β3-adrenergic pathway, helping relax the bladder’s smooth muscle during the storage phase. This allows the bladder to hold more urine and […]
Redemplo-Plozasiran
Redemplo (plozasiran) is a targeted therapy approved for the treatment of familial chylomicronemia syndrome (FCS) in adults, in combination with a strict low-fat diet. FCS is a rare genetic lipid disorder in which the body cannot properly break down fats, leading to extremely high triglyceride levels and recurrent episodes of acute pancreatitis. Redemplo is designed […]
Bysanti-Milsaperidone
Bysanti (milsaperidone) is an FDA-approved atypical antipsychotic indicated for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. As an oral therapy, Bysanti is designed to modulate key neurotransmitter pathways, particularly dopamine and serotonin receptor activity, which play a central role […]
Yuviwel-Navepegritide
Yuviwel (navepegritide) is an FDA-approved C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia who have open epiphyses. Achondroplasia is a rare genetic skeletal disorder characterized by impaired endochondral bone growth due to overactive FGFR3 signaling, resulting in disproportionate short stature and associated […]
Adquey-Difamilast
Adquey (Difamilast) is a topical phosphodiesterase-4 (PDE4) inhibitor developed for the treatment of atopic dermatitis (AD) in adult and pediatric patients aged 2 years and older. Adquey delivers targeted anti-inflammatory and antipruritic effects with a rapid onset of action, resulting in significant clinical improvement within the first week of treatment. Difamilast works by selectively inhibiting […]
